Moleculin Total Assets vs Accounts Payable Analysis

MBRX Stock  USD 1.29  0.02  1.57%   
Moleculin Biotech financial indicator trend analysis is infinitely more than just investigating Moleculin Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moleculin Biotech is a good investment. Please check the relationship between Moleculin Biotech Total Assets and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Total Assets vs Accounts Payable

Total Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moleculin Biotech Total Assets account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.
The correlation between Moleculin Biotech's Total Assets and Accounts Payable is 0.72. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Moleculin Biotech, assuming nothing else is changed. The correlation between historical values of Moleculin Biotech's Total Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Moleculin Biotech are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Assets i.e., Moleculin Biotech's Total Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.72
Relationship DirectionPositive 
Relationship StrengthSignificant

Total Assets

Total assets refers to the total amount of Moleculin Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Moleculin Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Accounts Payable

An accounting item on the balance sheet that represents Moleculin Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Moleculin Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Moleculin Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.Selling General Administrative is likely to drop to about 6.9 M in 2025. Issuance Of Capital Stock is likely to drop to about 180.4 K in 2025
 2022 2023 2024 2025 (projected)
Depreciation And Amortization222K127K114.3K108.6K
Interest Income240K1.2M1.1M965.1K

Moleculin Biotech fundamental ratios Correlations

-0.280.650.670.990.810.76-0.97-0.770.720.980.760.040.980.84-0.30.360.850.57-0.760.98-0.810.570.320.71-0.87
-0.280.280.3-0.360.2-0.040.36-0.260.31-0.31-0.17-0.31-0.310.010.150.110.130.20.18-0.280.09-0.18-0.280.20.05
0.650.280.960.570.880.77-0.52-0.910.770.550.71-0.030.550.85-0.050.580.910.83-0.710.57-0.70.520.230.78-0.76
0.670.30.960.570.880.82-0.52-0.950.880.560.750.070.560.9-0.220.690.940.91-0.740.59-0.780.610.350.86-0.82
0.99-0.360.570.570.770.67-0.99-0.680.60.990.69-0.050.990.76-0.240.220.790.44-0.680.99-0.710.450.210.59-0.78
0.810.20.880.880.770.67-0.76-0.940.760.790.61-0.270.790.87-0.240.440.970.71-0.60.8-0.70.40.130.73-0.8
0.76-0.040.770.820.670.67-0.62-0.790.840.630.860.390.630.87-0.180.660.80.81-0.850.66-0.790.810.570.84-0.88
-0.970.36-0.52-0.52-0.99-0.76-0.620.67-0.56-1.0-0.590.07-1.0-0.730.26-0.21-0.76-0.40.58-0.990.69-0.42-0.21-0.570.78
-0.77-0.26-0.91-0.95-0.68-0.94-0.790.67-0.89-0.69-0.720.01-0.69-0.950.34-0.66-0.97-0.870.7-0.720.82-0.63-0.37-0.90.91
0.720.310.770.880.60.760.84-0.56-0.890.60.80.230.60.86-0.330.660.840.84-0.780.63-0.860.690.440.94-0.86
0.98-0.310.550.560.990.790.63-1.0-0.690.60.6-0.091.00.76-0.270.230.790.43-0.61.0-0.70.430.20.6-0.79
0.76-0.170.710.750.690.610.86-0.59-0.720.80.60.370.60.8-0.270.570.740.74-1.00.63-0.830.770.510.78-0.8
0.04-0.31-0.030.07-0.05-0.270.390.070.010.23-0.090.37-0.090.18-0.160.49-0.060.32-0.36-0.06-0.430.670.760.38-0.28
0.98-0.310.550.560.990.790.63-1.0-0.690.61.00.6-0.090.76-0.270.230.790.43-0.61.0-0.70.430.20.6-0.79
0.840.010.850.90.760.870.87-0.73-0.950.860.760.80.180.76-0.460.750.960.9-0.790.78-0.890.80.590.92-0.97
-0.30.15-0.05-0.22-0.24-0.24-0.180.260.34-0.33-0.27-0.27-0.16-0.27-0.46-0.62-0.33-0.470.26-0.290.45-0.54-0.67-0.40.45
0.360.110.580.690.220.440.66-0.21-0.660.660.230.570.490.230.75-0.620.60.92-0.560.27-0.710.870.840.78-0.72
0.850.130.910.940.790.970.8-0.76-0.970.840.790.74-0.060.790.96-0.330.60.83-0.730.81-0.820.60.340.85-0.9
0.570.20.830.910.440.710.81-0.4-0.870.840.430.740.320.430.9-0.470.920.83-0.720.47-0.820.820.670.9-0.84
-0.760.18-0.71-0.74-0.68-0.6-0.850.580.7-0.78-0.6-1.0-0.36-0.6-0.790.26-0.56-0.73-0.72-0.620.81-0.76-0.5-0.760.78
0.98-0.280.570.590.990.80.66-0.99-0.720.631.00.63-0.061.00.78-0.290.270.810.47-0.62-0.730.470.230.63-0.81
-0.810.09-0.7-0.78-0.71-0.7-0.790.690.82-0.86-0.7-0.83-0.43-0.7-0.890.45-0.71-0.82-0.820.81-0.73-0.81-0.63-0.930.92
0.57-0.180.520.610.450.40.81-0.42-0.630.690.430.770.670.430.8-0.540.870.60.82-0.760.47-0.810.910.83-0.83
0.32-0.280.230.350.210.130.57-0.21-0.370.440.20.510.760.20.59-0.670.840.340.67-0.50.23-0.630.910.62-0.63
0.710.20.780.860.590.730.84-0.57-0.90.940.60.780.380.60.92-0.40.780.850.9-0.760.63-0.930.830.62-0.93
-0.870.05-0.76-0.82-0.78-0.8-0.880.780.91-0.86-0.79-0.8-0.28-0.79-0.970.45-0.72-0.9-0.840.78-0.810.92-0.83-0.63-0.93
Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets29.0M84.1M57.4M38.2M43.9M35.4M
Short Long Term Debt Total277K159K451K574K660.1K406.4K
Other Current Liab1.7M2.2M2.6M4.2M4.8M5.1M
Total Current Liabilities2.9M3.6M4.8M6.8M7.8M8.2M
Total Stockholder Equity17.8M79.0M52.2M26.1M30.0M28.9M
Net Tangible Assets3.1M4.4M6.6M67.8M78.0M81.9M
Net Debt(14.9M)(70.7M)(42.7M)(23.0M)(20.7M)(21.7M)
Retained Earnings(56.9M)(72.8M)(101.8M)(131.6M)(118.4M)(112.5M)
Accounts Payable1.1M1.4M2.1M2.5M2.9M1.5M
Cash15.2M70.9M43.1M23.6M27.1M22.4M
Non Current Assets Total11.8M11.6M11.8M11.9M13.7M11.4M
Non Currrent Assets Other(11.8K)338K275K(1.0)(0.9)(0.85)
Cash And Short Term Investments15.2M70.9M43.1M23.6M27.1M22.4M
Common Stock Shares Outstanding656.4K1.8M1.9M2.0M1.8M1.6M
Liabilities And Stockholders Equity29.0M84.1M57.4M38.2M43.9M35.4M
Non Current Liabilities Total8.4M1.5M412K5.3M6.1M6.4M
Other Stockholder Equity74.5M151.7M154.0M157.7M181.3M190.4M
Total Liab11.3M5.1M5.2M12.1M14.0M14.7M
Total Current Assets17.2M72.5M45.6M26.3M30.2M24.0M
Accumulated Other Comprehensive Income65K41K12K(9K)(10.4K)(9.8K)
Short Term Debt118K96K116K100K90K174.4K
Common Stock29K46K69K33K38.0K33.6K
Other Liab1.4M5.8M8.2M1.4M1.6M3.1M
Property Plant And Equipment Net685K445K678K796K915.4K512.3K
Inventory1.9M(45K)(22K)1.00.90.86
Other Current Assets2.0M1.1M1.6M2.6M3.0M3.2M
Property Plant And Equipment Gross685K1.1M678K1.7M1.9M2.0M
Property Plant Equipment463K603K685K445K511.8K412.9K
Net Invested Capital17.8M79.0M52.2M26.1M30.0M34.9M
Net Working Capital14.3M68.9M40.8M19.5M22.4M25.7M
Net Receivables1K45K22K99K113.9K119.5K
Capital Lease Obligations277K159K451K574K660.1K404.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.